Other Events. On August 21, 2026, MannKind Corporation (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission. This Current Report on Form 8-K is being filed for the purpose of filing the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares of common stock of the Company set forth in the prospectus supplement, which opinion is filed as Exh…

Results of Operations and Financial Condition. On August 5, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Unregistered Sales of Equity Securities. On July 23, 2026, MannKind Corporation, a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors an aggregate of 10,440,838 shares (“Shares”) of the Company’s common stock, par value $0.01 (“Common Stock”), at a purchase price of $3.89 per Share, and in lieu of shares of Common Stock, pre…

Results of Operations and Financial Condition. On May 6, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On February 26, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On November 5, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Entry into a Material Definitive Agreement. On August 24, 2025 MannKind Corporation (“MannKind”) entered into a first amendment (“First Amendment”) to the global license and collaboration agreement dated September 3, 2018 (the “License Agreement”) with United Therapeutics Corporation (“United Therapeutics”). The First Amendment memorializes the exercise of United Therapeutics’ option to expand the scope of the products covered by the License Agreement to include an additional development prod…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On August 24, 2025, MannKind Corporation, a Delaware corporation (“ Parent ”), Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“ Purchaser ”), and scPharmaceuticals Inc., a Delaware corporation (the “ Target ”), entered into a definitive Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which Parent, through Purchaser, will commence a tender offer (the…

or Exhibits 99.1 and 99.2 . Forward-Looking Statements This report contains forward-looking statements. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These forward-looking statements include, without limitation, statements related to the proposed Offer, Merger and related transactions contemplated by the Merger Agreement and the CVR Agreement and the expected timin…

Results of Operations and Financial Condition. On August 6, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Chief Medical Officer and Executive Vice President, Research & Development — Burkhard Blank: Mr. Blank stepped down from his executive role with a transition and separation agreement.

Results of Operations and Financial Condition. On May 8, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On February 26, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Executive Vice President, Operations — Lauren Sabella: Lauren Sabella is retiring from her role, but will continue in an executive position until July 18, 2025.

Other Events. On December 17, 2024, MannKind Corporation, (the “Company”) entered into separate, privately negotiated exchange agreements with certain holders (the “Holders”) of the Company’s 2.50% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of approximately $193.7 million of Notes held by them in exchange for an aggregate of 26,749,559 shares of the Company’s common stock (“Shares”).…

Unregistered Sales of Equity Securities. The disclosure under

Results of Operations and Financial Condition. On November 7, 2024, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Director — Kent Kresa: Kent Kresa is retiring from the Board of Directors, and Steven B. Binder has been appointed to succeed him.

Results of Operations and Financial Condition. On August 7, 2024, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On May 8, 2024, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Other Events. On April 1, 2024, MannKind Corporation (the “Company”) repaid in full all outstanding indebtedness and terminated all commitments and obligations under its Credit and Security Agreement, dated as of August 6, 2019 (as amended, the “Loan Agreement”), between the Company, MannKind LLC (“MannKind LLC”), QrumPharma, Inc. (“QP”), Technosphere International, Inc. (“Technosphere,” Technosphere, together with MannKind, MannKind LLC and QP, each a “Borrower” and collectively, the “Borrow…

Results of Operations and Financial Condition. On February 27, 2024, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Entry Into a Material Definitive Agreement. On December 27, 2023, MannKind Corporation (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Funding Partners Borrower 2 SPE, LP (“Sagard”) for the sale to Sagard of a 1% royalty on global net sales of Tyvaso DPI ® (treprostinil) inhalation powder (“Tyvaso DPI”) occurring on and after October 1, 2023 through December 31, 2042 under the Company’s License and Collaboration Agreement dated as o…

Entry Into a Material Definitive Agreement. On December 22, 2023, MannKind Corporation (the “Company”) entered into a Seventh Amendment to Supply Agreement (the “Seventh Amendment”) with Amphastar Pharmaceuticals, Inc. pursuant to which the parties amended the Supply Agreement, dated July 31, 2014, as amended (the “Supply Agreement”). Pursuant to the Seventh Amendment, the parties agreed to, among other things, accommodate a change in the source of inclusion bodies (an intermediate product in…

Results of Operations and Financial Condition. On November 7, 2023, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.